Cho KiHo, Noh KiHwan, Jung WooSang, Park SeongUk, Moon SangKwan, Park JungMi, Ko ChangNam, Kim YoungSuk, Bae HyungSup
Department of Cardiovascular and Neurologic Diseases (Stroke Center), College of Oriental Medicine, Kyung-Hee University, Seoul, Korea.
Neurol Res. 2008 Jul;30(6):655-8. doi: 10.1179/174313208X305382. Epub 2008 May 21.
Chunghyul-dan is a combinatorial herbal medicine, and previous works reported that it had therapeutic effects for microangiopathy, which is a major part in the progression of small vessel disease, as having anti-hypertensive, anti-hyperlipidemic, anti-apoptotic, anti-oxidative and anti-inflammatory activities. Therefore, we examined the inhibitory effect of Chunghyul-dan on stroke recurrence in patients with small vessel disease.
We prescribed Chunghyul-dan 600 mg a day to the patients with small vessel disease, and monitored stroke recurrence, drug compliances and adverse effect for 2 years. And then we performed follow-up brain MRI to find new vascular lesion after 2 years of Chunghyul-dan medication. As for the control, we recruited the subjects who had been managed with antiplatelet agents from a western medical hospital, and compared the rate of stroke recurrence.
There were 148 subjects who had been treated with Chunghyul-dan for 2 years, and new vascular events were found in three subjects. On the other hand, 208 subjects were managed with anti-platelet agents for 2 years in a Western medical hospital, and 17 of them had stroke recurrence. Therefore, 2 years of Chunghyul-dan medication reduced the odds ratio of stroke recurrence by 77% compared to the anti-platelet agents managed control. The inhibition rate increased to 79%, when adjusted for other relevant risk factors for stroke occurrence. During the study, no adverse effect was detected.
We suggest that Chunghyul-dan could be useful for inhibition of stroke recurrence by preventing the progression of microangiopathy. Further study with a randomized controlled trial is needed to confirm this suggestion.
Chunghyul-dan是一种复方草药，既往研究报道其具有抗高血压、抗高血脂、抗凋亡、抗氧化和抗炎活性，对微血管病变具有治疗作用，而微血管病变是小血管疾病进展的主要部分。因此，我们研究了Chunghyul-dan对小血管疾病患者中风复发的抑制作用。
我们给小血管疾病患者每天服用600mg Chunghyul-dan，监测中风复发情况、药物依从性和不良反应，为期2年。然后在服用Chunghyul-dan 2年后进行脑部MRI随访，以发现新的血管病变。作为对照，我们招募了一家西医医院中接受抗血小板药物治疗的受试者，并比较中风复发率。
148名受试者接受了2年的Chunghyul-dan治疗，其中3名受试者出现了新的血管事件。另一方面，208名受试者在一家西医医院接受了2年的抗血小板药物治疗，其中17人中风复发。因此，与接受抗血小板药物治疗的对照组相比，服用2年Chunghyul-dan可使中风复发的比值比降低77%。在对其他与中风发生相关的危险因素进行调整后，抑制率提高到79%。在研究过程中，未检测到不良反应。
我们认为Chunghyul-dan可能通过预防微血管病变的进展来抑制中风复发。需要进一步进行随机对照试验来证实这一观点。
